The phenotypic data of the study participants are shown in Table 1. The PUD patients had a more common family history of peptic ulcer (p = 0.0005), alcohol (p = 0.0005) and tobacco (p = 0.0005) consumption, stress (p = 0.0005), the presence of cardiovascular pathology (p = 0.0005) versus control group. These parameters were used as confounding factors (covariates) in the regression association analyses.
Table 1
Phenotypic characteristics of the study participants.
Parameters
|
Control
mean ± SD, % (n)
|
PUD
mean ± SD, % (n)
|
p
|
N
|
347
|
798
|
-
|
Age, years
(min–max)
|
48.47 ± 13.69
(22–79)
|
48.54 ± 14.28
(20–79)
|
0.92
|
Gender ratio, f/m
|
66.28/33.72
(230/117)
|
67.42/32.58 (538/260)
|
0.76
|
BMI, kg/m2
|
26.83 ± 5.09
|
26.94 ± 5.30
|
0.78
|
Age of developing peptic ulcer, years
|
-
|
41.12 ± 12.87
|
-
|
Family history of peptic ulcer
|
4.32 (15)
|
18.29 (146)
|
0.0005
|
Current smoking
|
14.99 (52)
|
33.08 (264)
|
0.0005
|
Alcohol consumption
|
32.28 (112)
|
51.13 (408)
|
0.0005
|
Stress
|
37.17 (129)
|
77.19 (616)
|
0.0005
|
Positivity H. pylori test (endoscopic biopsy and histological identification)
|
-
|
50.63 (404)
|
-
|
PUD characteristics
|
Location
Stomach: Body
Pylorus
Antrum
Duodenum: Bulb
|
-
-
-
-
|
2.76 (22)
3.01 (24)
48.62 (388)
45.61 (364)
|
-
-
-
-
|
Sizes ulcer (diameter) (cm)
|
-
|
0.61 ± 0.40
|
-
|
Sizes ulcer: Small (< 0.5 cm)
Medium (0.5-1.0 cm)
Large (> 1.0 cm)
|
-
-
-
|
45.37 (362)
44.86 (358)
9.77 (78)
|
-
-
-
|
PUD associated complications
|
Bleeding
|
-
|
3.51 (28)
|
-
|
Perforation
|
-
|
8.27 (66)
|
-
|
Stenosis
|
-
|
6.52 (52)
|
-
|
Malignancy
|
-
|
2.26 (18)
|
-
|
Other somatic pathologies
|
Cardiovascular pathology
|
26.80 (93)
|
48.37 (386)
|
0.0005
|
Endocrine pathology
|
3.17 (11)
|
5.01 (40)
|
0.22
|
Kidney pathology
|
2.59 (9)
|
3.76 (30)
|
0.41
|
Respiratory system pathology
|
4.32 (15)
|
5.76 (46)
|
0.39
|
Nervous system pathology
|
7.78 (27)
|
9.52 (76)
|
0.40
|
Musculoskeletal system pathology
|
6.91 (24)
|
8.02 (64)
|
0.60
|
p values < 0.05 are shown in bold. |
Supplementary Table S1 shows distributions of genotypes and alleles of the ten studied SNPs in the PUD patients and control groups. All analyzed SNPs were in the HWE (p > 0.005, pbonf>0.05). After the Bonferroni correction, only polymorphisms of the MMP9 gene manifested association with PUD (Table 2). Specifically, the increased risk of PUD was associated with allele G of SNP rs17576 (additive model, the odds ratio adjusted for confounding factors ORadj = 1.31, pperm = 0.016, power − 82.98%) (Table 2). Two loci were associated with H. pylori-positive PUD (rs3918249 and rs17576) (Table 3). Allele C of SNP rs3918249 showed a significant association with the increased risk of H. pylori-positive PUD (dominant model, ORadj = 1.82, pperm = 0.002, power − 96.43%). The increased risk of H. pylori-positive PUD was also associated with a carriage of allele G of loci rs17576 according to the all three genetic models: additive (ORadj = 1.53, pperm = 0.001, power − 98.14%), dominant (ORadj = 1.67, pperm = 0.013, power − 90.21%), recessive (ORadj = 1.95, pperm = 0.007, power − 94.75%).
Table 2
Associations of the MMP gene polymorphisms with PUD.
SNP
|
Gene
|
MAF
|
n
|
Additive model
|
Dominant model
|
Recessive model
|
OR
|
95% CI
|
Р
|
OR
|
95% CI
|
Р
|
OR
|
95% CI
|
Р
|
L95
|
U95
|
L95
|
U95
|
L95
|
U95
|
rs1940475
|
MMP-8
|
T
|
1136
|
0.96
|
0.79
|
1.18
|
0.708
|
0.91
|
0.66
|
1.26
|
0.573
|
0.99
|
0.71
|
1.39
|
0.960
|
rs1799750
|
MMP-1
|
2G
|
1107
|
0.89
|
0.73
|
1.09
|
0.263
|
0.86
|
0.62
|
1.19
|
0.362
|
0.84
|
0.59
|
1.02
|
0.345
|
rs679620
|
MMP-3
|
T
|
1133
|
0.97
|
0.79
|
1.20
|
0.797
|
0.93
|
0.66
|
1.30
|
0.655
|
1.01
|
0.72
|
1.41
|
0.979
|
rs243865
|
MMP-2
|
T
|
1121
|
0.96
|
0.76
|
1.22
|
0.749
|
0.94
|
0.69
|
1.27
|
0.672
|
1.01
|
0.57
|
1.80
|
0.969
|
rs3918242
|
MMP-9
|
T
|
1127
|
1.00
|
0.75
|
1.32
|
0.973
|
1.06
|
0.77
|
1.46
|
0.733
|
0.58
|
0.22
|
1.52
|
0.266
|
rs3918249
|
MMP-9
|
C
|
1125
|
1.16
|
0.93
|
1.43
|
0.181
|
1.45
|
1.07
|
1.97
|
0.018
|
0.88
|
0.59
|
1.33
|
0.549
|
rs17576
|
MMP-9
|
G
|
1140
|
1.31
|
1.05
|
1.60
|
0.016
|
1.35
|
0.99
|
1.83
|
0.054
|
1.51
|
1.00
|
2.27
|
0.048
|
rs3787268
|
MMP-9
|
A
|
1133
|
1.12
|
0.87
|
1.45
|
0.384
|
1.17
|
0.86
|
1.58
|
0.315
|
1.02
|
0.48
|
2.14
|
0.968
|
rs2250889
|
MMP-9
|
G
|
1128
|
0.79
|
0.57
|
1.09
|
0.148
|
0.77
|
0.53
|
1.12
|
0.172
|
0.63
|
0.22
|
1.80
|
0.388
|
rs17577
|
MMP-9
|
A
|
1112
|
1.00
|
0.75
|
1.32
|
0.988
|
1.01
|
0.80
|
1.52
|
0.563
|
0.46
|
0.18
|
1.17
|
0.102
|
All results were obtained after adjustment for covariates. |
ОR, odds ratio. |
95% CI, 95% confidence interval. |
p values < 0.017 are shown in bold. |
Table 3
Associations of the MMP gene polymorphisms with H. pylori-positive and H. pylori-negative PUD.
SNP
|
Gene
|
MAF
|
n
|
Additive model
|
Dominant model
|
Recessive model
|
OR
|
95% CI
|
Р
|
OR
|
95% CI
|
Р
|
OR
|
95% CI
|
Р
|
L95
|
U95
|
L95
|
U95
|
L95
|
U95
|
H. pylori-positive PUD
|
rs1940475
|
MMP-8
|
T
|
744
|
0.97
|
0.76
|
1.23
|
0.774
|
0.91
|
0.62
|
1.36
|
0.656
|
0.99
|
0.66
|
1.49
|
0.979
|
rs1799750
|
MMP-1
|
2G
|
725
|
0.88
|
0.69
|
1.13
|
0.313
|
0.83
|
0.56
|
1.23
|
0.361
|
0.85
|
0.55
|
1.31
|
0.452
|
rs679620
|
MMP-3
|
T
|
743
|
0.92
|
0.71
|
1.18
|
0.505
|
0.85
|
0.57
|
1.28
|
0.447
|
0.93
|
0.62
|
1.42
|
0.744
|
rs243865
|
MMP-2
|
T
|
735
|
0.98
|
0.74
|
1.30
|
0.879
|
0.90
|
0.63
|
1.30
|
0.588
|
1.26
|
0.64
|
2.46
|
0.509
|
rs3918242
|
MMP-9
|
T
|
739
|
1.17
|
0.83
|
1.63
|
0.376
|
1.34
|
0.92
|
1.96
|
0.127
|
0.30
|
0.06
|
1.39
|
0.123
|
rs3918249
|
MMP-9
|
C
|
737
|
1.33
|
1.03
|
1.72
|
0.031
|
1.82
|
1.23
|
2.67
|
0.002
|
1.03
|
0.63
|
1.67
|
0.914
|
rs17576
|
MMP-9
|
G
|
746
|
1.53
|
1.19
|
1.98
|
0.001
|
1.67
|
1.14
|
2.43
|
0.008
|
1.95
|
1.22
|
3.11
|
0.005
|
rs3787268
|
MMP-9
|
A
|
745
|
1.23
|
0.91
|
1.67
|
0.181
|
1.26
|
0.87
|
1.81
|
0.219
|
1.43
|
0.62
|
3.30
|
0.396
|
rs2250889
|
MMP-9
|
G
|
736
|
0.77
|
0.51
|
1.15
|
0.203
|
0.78
|
0.49
|
1.23
|
0.282
|
0.42
|
0.09
|
2.01
|
0.280
|
rs17577
|
MMP-9
|
A
|
728
|
1.20
|
0.86
|
1.68
|
0.271
|
1.43
|
0.98
|
2.09
|
0.067
|
0.37
|
0.10
|
1.35
|
0.132
|
H. pylori-negative PUD
|
rs1940475
|
MMP-8
|
T
|
738
|
0.98
|
0.77
|
1.25
|
0.893
|
0.94
|
0.63
|
1.39
|
0.752
|
1.02
|
0.68
|
1.53
|
0.920
|
rs1799750
|
MMP-1
|
2G
|
721
|
0.91
|
0.71
|
1.17
|
0.459
|
0.90
|
0.61
|
1.33
|
0.596
|
0.86
|
0.56
|
1.32
|
0.483
|
rs679620
|
MMP-3
|
T
|
735
|
0.86
|
0.67
|
1.10
|
0.235
|
0.79
|
0.53
|
1.19
|
0.258
|
0.84
|
0.55
|
1.28
|
0.419
|
rs243865
|
MMP-2
|
T
|
729
|
0.94
|
0.70
|
1.26
|
0.696
|
0.97
|
0.67
|
1.39
|
0.849
|
0.80
|
0.39
|
1.67
|
0.558
|
rs3918242
|
MMP-9
|
T
|
731
|
0.83
|
0.59
|
1.18
|
0.296
|
0.80
|
0.53
|
1.20
|
0.276
|
0.83
|
0.28
|
2.46
|
0.739
|
rs3918249
|
MMP-9
|
C
|
733
|
1.00
|
0.78
|
1.30
|
0.975
|
1.15
|
0.80
|
1.66
|
0.448
|
0.77
|
0.46
|
1.30
|
0.323
|
rs17576
|
MMP-9
|
G
|
740
|
1.08
|
0.83
|
1.40
|
0.569
|
1.09
|
0.76
|
1.57
|
0.626
|
1.12
|
0.67
|
1.88
|
0.660
|
rs3787268
|
MMP-9
|
A
|
733
|
1.01
|
0.74
|
1.40
|
0.930
|
1.09
|
0.75
|
1.57
|
0.656
|
0.62
|
0.21
|
1.77
|
0.367
|
rs2250889
|
MMP-9
|
G
|
734
|
0.81
|
0.55
|
1.20
|
0.293
|
0.78
|
0.49
|
1.22
|
0.268
|
0.82
|
0.25
|
2.07
|
0.739
|
rs17577
|
MMP-9
|
A
|
724
|
0.80
|
0.57
|
1.14
|
0.217
|
0.81
|
0.54
|
1.22
|
0.310
|
0.53
|
0.17
|
1.65
|
0.270
|
All results were obtained after adjustment for covariates. |
ОR, odds ratio. |
95% CI, 95% confidence interval. |
p values < 0.017 are shown in bold. |
Haplotype AACG defined by rs17576-rs3787268-rs2250889-rs17577 was associated with PUD (ORadj=0.17, p = 0.001, рperm=0.003), haplotype CG defined by rs3918249-rs17576 of the MMP9 gene was associated with H. pylori-positive PUD (ORadj=1.49, p = 0.004, рperm=0.009) (Fig. 1). Thus, in total five polymorphisms of the MMP9 gene were associated with PUD (two individually and three within haplotypes).
Functional SNP
Non-synonymous SNPs. Among the PUD-associated SNPs, three polymorphisms (rs17576, rs2250889, and rs17577) were missense (Supplementary Table S2).
Regulatory effects. The data on the regulatory effects of the PUD-associated loci of the MMP9 gene are presented in Supplementary Table S3. According to the HaploReg database, three SNPs were located in evolutionarily conserved regions, all five polymorphisms - in the region of DNA binding with modified histone (H3K4me3, H3K9ac) marking promoters and hypersensitivity region to DNAse-1 in various tissues, four SNPs – in the region of DNA binding with modified histone (H3K4me1, H3K27ac) marking enhancers and two polymorphisms - in the protein-bound region. Importantly, the PUD-associated SNPs manifest their regulatory effects in the tissues and organs related to the pathogenesis of the disease (fetal stomach and small intestine, adult gastric and small intestine, adult stomach and duodenum mucosa, etc.).
In addition to the five PUD-associated SNPs, regulatory significance was estimated for 50 polymorphisms linked to them (Supplementary Table S3). Three synonymous SNPs were located in exons of the MMP9 gene, 28 SNPs were in 5'-UTR of the MMP9, ZNF335, and SLC12A5 genes, 19 were in introns. Ten loci were located in evolutionarily conserved regions. The in silico analysis of the linked SNPs suggested several polymorphisms with pronounced regulatory effects (Supplementary Table S3). For example, rs3848722 (was in linkage disequilibrium with SNPs rs3918249 and rs17576) is located in the hypersensitive region to DNAase-I (19 tissues), in the region of DNA binding with modified histone marking promoters and enhancers (5 and 14 tissues respectively), and a putative transcription factor binding sites (Pax-6, HNF4, ZID, NRSF).
Expression QTLs. In silico analysis for the eQTL impact of the PUD-associated SNPs shows their might affect the expression of 17 genes (MMP9, CD40, NTTIP1, NEURL2, PCIF1, PLTP, RP11-465L10.10, RP3-337O18.9, RPL13P2, SLC12A5, SNX21, SPATA25, SYS1, WFDC10B, WFDC3, ZNF335, ZSWIM1) in more than 20 tissues and organs (Supplementary Table S4). The PUD-associated loci were also in strong LD with the 48 SNPs affecting the expression of the above 17 genes in various organs and tissues (Supplementary Table S5).
Splicing QTLs. The PUD-associated SNPs had possess the potential impact on the genes alternative splicing and might sQTL affect for 4 genes (PLTP, ACOT8, SNX21, SLC12A5) (Supplementary Table S6). These loci were tightly linked to 48 polymorphisms affecting sQTL of the above four genes in more than 20 tissues and organs (Supplementary Table S7).